Recent Updates
Recently added Catalysts
LSTA Positive Sentiment Score: 75/100

Lisata Therapeutics to Present at BIO CEO & Investor Conference

Key Takeaway: Lisata Therapeutics, Inc. announced that its CEO, Dr. David J. Mazzo, will present at the BIO CEO & Investor Conference on February 26-27, 2024. The company is known for developing therapies for advanced solid tumors and expects to share significant clinical and business milestones in the coming years. Management will also hold one-on-one meetings with investors during the conference.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lisata is set to present at a key industry conference, indicating active engagement with investors.
  • The company's innovative therapy for treating advanced solid tumors showcases potential for significant impact.
  • Lisata projects numerous clinical and business milestones in the next two years, suggesting future growth.

Full Press Release Details

BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.
Dr. Mazzo’s presentation is on Monday, February 26, 2024 at 11:15 a.m. Eastern time. Management will also be available for in-person one-on-one meetings with investors. For those interested in meeting with management during the conference, please request a meeting through the online conference platform or reach out to John Menditto, VP of Investor Relations and Corporate Communications, at jmenditto@lisata.com. For more information regarding the BIO CEO & Investor Conference, please visit the conference website.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. For more information on the Company, please visit www.lisata.com.
Investors and Media:
Lisata Therapeutics, Inc.
Vice President, Investor Relations and Corporate Communications

Frequently Asked Questions

When will Lisata Therapeutics present at the BIO CEO & Investor Conference?

Lisata Therapeutics will present on February 26, 2024, at 11:15 a.m. Eastern time.

Who is the CEO of Lisata Therapeutics?

David J. Mazzo, Ph.D., is the President and CEO of Lisata Therapeutics.

What is Lisata’s lead product candidate?

Lisata’s lead product candidate is LSTA1, designed to target solid tumors effectively.

How can investors meet Lisata’s management at the conference?

Investors can request meetings via the online platform or contact John Menditto directly.

What technology does Lisata Therapeutics utilize?

Lisata uses the CendR Platform® Technology for its innovative drug delivery approach.

Last updated: Feb 20, 2024